This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Chiron Turns Around Bottom Line

"We are pleased with our achievements in the past year, particularly our return to the U.S. influenza vaccine market," Pien said in a prepared statement.

Manufacturing problems caused Chiron to cancel all sales of its Fluvirin vaccine in the U.S. during the 2004-05 season. Chiron returned to the market during the 2005-06 season, albeit with a reduced supply of vaccine. Chiron sold 13 million doses of Fluvirin during the current season.

Pien said Chiron should have the manufacturing capacity to produce 40 million doses for the 2006-07, but he added that capacity doesn't equal actual sales.

Fluvirin sales played a role in the improved fourth-quarter and full-year performance, he said, as did expanded royalty and license revenue. Chiron benefited from an 11% tax rate during 2005 vs. 28% in 2004 on a GAAP basis. The reduced tax rate was caused by lower profits in certain foreign locations and the transfer of some product rights in 2004. Chiron doesn't expect such a low tax rate this year.

For all of 2005, the company reported GAAP earnings of $186.6 million, or 97 cents a share, on revenue of $1.92 billion. In the previous year, it earned $78.9 million, or 41 cents a share, on revenue of $1.72 billion.

Among major business units, Chiron said vaccine sales rose 18% to $604 million during 2005. Blood-testing revenue gained 12% to $556 million, and drug revenue added 6% to $629 million. Royalty and licensing fees rose 9% to $317 million.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
NVS $102.46 0.00%
AAPL $124.75 0.00%
FB $80.78 0.00%
GOOG $524.05 0.00%
TSLA $206.79 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs